Riluzole treatment paradoxically increases motoneuron excitability in ALS due to hyperactive homeostasis

Area of Science:

• Neuroscience
• Neurodegenerative Diseases
• Pharmacology

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder with limited treatment options.
• Riluzole is a primary therapy for ALS, but its clinical benefits are modest and often wane.
• Previous research indicated hyperactive homeostatic mechanisms in ALS mouse models.

Purpose of the Study:

• To investigate if dysregulated homeostatic mechanisms in ALS antagonize the therapeutic effects of riluzole.
• To examine the impact of riluzole on motoneuron excitability and synaptic inputs in an ALS mouse model.

Main Methods:

• Wild-type (WT) and SOD1 G93A (mSOD1) mice received riluzole or placebo.
• Intracellular recordings were used to assess motoneuron excitability and synaptic inputs in the sacral spinal cord.
• Membrane capacitance was measured to evaluate motoneuron size.

Main Results:

• Riluzole increased motoneuron excitability and polysynaptic inputs in mSOD1 mice, but not WT mice.
• ALS motoneurons showed larger membrane capacitance, which riluzole reduced to WT levels.
• These findings suggest ALS-related homeostatic mechanisms counteract riluzole's suppressive actions.

Conclusions:

• Hyperactive homeostatic mechanisms in ALS may limit riluzole's clinical efficacy.
• Riluzole demonstrated a potential neuroprotective effect by normalizing motoneuron size and reducing metabolic demand in mSOD1 mice.
• Understanding these interactions could inform future ALS therapeutic strategies.